NCT02713737

Brief Summary

The investigators hypothesized that heated humidified high-flow nasal cannula oxygen(HFNC) along with high quality of sleep, in comparison with noninvasive positive pressure ventilation (NIV), could reduce the release of inflammatory marker C-reactive protein(CRP), which as independent predictor of atrial fibrillation(AF), further lower the incidence of new-onset AF following coronary artery bypass grafting(CABG).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Apr 2016

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 25, 2016

Completed
25 days until next milestone

First Posted

Study publicly available on registry

March 21, 2016

Completed
11 days until next milestone

Study Start

First participant enrolled

April 1, 2016

Completed
6.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2023

Completed
Last Updated

March 9, 2021

Status Verified

March 1, 2021

Enrollment Period

6.7 years

First QC Date

February 25, 2016

Last Update Submit

March 6, 2021

Conditions

Keywords

hypoxemiahigh-flowatrial fibrillationsleep

Outcome Measures

Primary Outcomes (1)

  • Incidence of atrial fibrillation

    from ICU admission to discharge

    10 days

Secondary Outcomes (8)

  • PO2/FiO2(P/F)

    5 days

  • Lactate levels

    5 days

  • intubation time

    5 days

  • transfusion requirement

    5 days

  • inotropic usage

    5 days

  • +3 more secondary outcomes

Study Arms (2)

HFNC group

EXPERIMENTAL

HFNC: Heated humidified high-flow nasal cannula.

Device: heated humidified high-flow nasal cannula

NIV group

ACTIVE COMPARATOR

NIV: Noninvasive ventilation.

Device: noninvasive ventilation

Interventions

HFNC device (Airvo™, Fisher&Paykel, Auckland, New Zealand) with a heated circuit (Fisher&Paykel,900PT501) and nasal cannula(optiflow TM,Fisher&Paykel). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) \> 92%.

HFNC group

TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 \> 92%.

Also known as: noninvasive positive pressure ventilation
NIV group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Hypoxemic respiratory failure

You may not qualify if:

  • Cardiac or respiratory arrest

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Henan Provincial People' Hospital

Zhengzhou, Henan, 450003, China

RECRUITING

Related Publications (7)

  • Meier-Ewert HK, Ridker PM, Rifai N, Regan MM, Price NJ, Dinges DF, Mullington JM. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol. 2004 Feb 18;43(4):678-83. doi: 10.1016/j.jacc.2003.07.050.

    PMID: 14975482BACKGROUND
  • Chanques G, Constantin JM, Sauter M, Jung B, Sebbane M, Verzilli D, Lefrant JY, Jaber S. Discomfort associated with underhumidified high-flow oxygen therapy in critically ill patients. Intensive Care Med. 2009 Jun;35(6):996-1003. doi: 10.1007/s00134-009-1456-x. Epub 2009 Mar 18.

    PMID: 19294365BACKGROUND
  • Ucar HI, Tok M, Atalar E, Dogan OF, Oc M, Farsak B, Guvener M, Yilmaz M, Dogan R, Demircin M, Pasaoglu I. Predictive significance of plasma levels of interleukin-6 and high-sensitivity C-reactive protein in atrial fibrillation after coronary artery bypass surgery. Heart Surg Forum. 2007;10(2):E131-5. doi: 10.1532/HSF98.20061175.

    PMID: 17597037BACKGROUND
  • Cuquemelle E, Pham T, Papon JF, Louis B, Danin PE, Brochard L. Heated and humidified high-flow oxygen therapy reduces discomfort during hypoxemic respiratory failure. Respir Care. 2012 Oct;57(10):1571-7. doi: 10.4187/respcare.01681. Epub 2012 Mar 12.

    PMID: 22417569BACKGROUND
  • Elliott R, Rai T, McKinley S. Factors affecting sleep in the critically ill: an observational study. J Crit Care. 2014 Oct;29(5):859-63. doi: 10.1016/j.jcrc.2014.05.015. Epub 2014 May 29.

    PMID: 24973105BACKGROUND
  • Stephan F, Barrucand B, Petit P, Rezaiguia-Delclaux S, Medard A, Delannoy B, Cosserant B, Flicoteaux G, Imbert A, Pilorge C, Berard L; BiPOP Study Group. High-Flow Nasal Oxygen vs Noninvasive Positive Airway Pressure in Hypoxemic Patients After Cardiothoracic Surgery: A Randomized Clinical Trial. JAMA. 2015 Jun 16;313(23):2331-9. doi: 10.1001/jama.2015.5213.

    PMID: 25980660BACKGROUND
  • Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol. 2007 Apr 17;49(15):1642-1648. doi: 10.1016/j.jacc.2006.12.042. Epub 2007 Apr 2.

MeSH Terms

Conditions

HypoxiaAtrial Fibrillation

Interventions

Noninvasive Ventilation

Condition Hierarchy (Ancestors)

Signs and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsArrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic Processes

Intervention Hierarchy (Ancestors)

Respiration, ArtificialAirway ManagementTherapeuticsRespiratory Therapy

Study Officials

  • Zhaoyun Cheng, MD

    Henan Provincial People' Hospital

    STUDY DIRECTOR

Central Study Contacts

You Zhang, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
associate professor

Study Record Dates

First Submitted

February 25, 2016

First Posted

March 21, 2016

Study Start

April 1, 2016

Primary Completion

December 1, 2022

Study Completion

April 1, 2023

Last Updated

March 9, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations